Cat.No. : CSC-RO0252 Host Cell: K562
| Cat. No. | CSC-RO0252 |
| Description | K562-CD19 cell line is derived from K562 which has been engineered to stably express CD19. |
| Gene | CD19 |
| Host Cell | K562 |
| Host Cell Species | Homo sapiens (Human) |
| Stability | Validated for at least 10 passages |
| Application | 1. Gene expression studies 2. Signaling pathway research 3. Drug screening and toxicology 4. Disease research |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Storage | Liquid nitrogen |
| Revival | Rapidly thaw cells in a 37°C water bath. Transfer contents into a tube containing pre-warmed media. Centrifuge cells and seed into a 25 cm2 flask containing pre-warmed media. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
The researchers genetically engineered T cells to express chimeric antigen receptors (CARs) that recognize tumor-associated antigens. They constructed and compared two CARs containing single-chain variable region fragments (scFv) that recognize CD19, one of which contained the signaling portion of the 4-1BB molecule and the other did not. The CAR without 4-1BB was ultimately selected for further preclinical development, and it was demonstrated that the gamma retrovirus encoding the receptor could transduce human T cells. Transduced anti-CD19-CAR CD8+ and CD4+ T cells specifically produced interferon-γ and interleukin-2 when faced with CD19+ target cells and effectively killed primary chronic lymphocytic leukemia (CLL) cells. T cells from CLL patients who had undergone chemotherapy were successfully transduced and sufficient numbers of T cells for clinical treatment after primary and secondary stimulation. In preparation for a clinical trial in patients with advanced B-cell malignancies, the researchers generated cell clones that produced retroviruses for anti-CD19 CARs and produced sufficient retroviral supernatant under good manufacturing practice (GMP) conditions.
Figure 1. The researchers cloned the CD19 gene into the MSGV vector, transfected K562 cells with the retrovirus, and screened them using flow cytometry to obtain CD19-K562 cells. Similarly, the NGFR gene was cloned and transfected to obtain NGFR-K562 cells. These cells were used to detect the specific recognition of CAR-T cells for CD19. (Kochenderfer JN, et al., 2009)
A: The CD19 Stable Cell Line - K562, which expresses the CD19 protein, can be utilized to study the behavior of B cell malignancies like chronic lymphocytic leukemia (CLL). Researchers can test the efficacy of CD19-directed therapies, such as monoclonal antibodies or CAR-T cell therapies, in inhibiting the growth and survival of these cells.
A: The cell line can be used to investigate the signaling pathways involved in B cell activation, proliferation, and differentiation, with a focus on the function of CD19 in these processes. This can provide insights into the normal B cell biology and how its dysregulation contributes to the development of B cell disorders.
A: By generating isogenic cell lines that express different CD19 mutations found in patient tumors, researchers can use this cell line to test personalized treatment strategies. This can help in understanding the variability in patient response to CD19-targeted therapies and guide the development of tailored treatment approaches.
A: The cell line can be used in high-throughput screening assays to identify compounds that effectively target CD19-expressing B cell lymphomas. This can accelerate the discovery of new drugs that are more potent and specific for the treatment of these cancers.
A: The cell line can be employed to model the interactions between B cells and other immune cells, such as T cells and macrophages. By studying these interactions, researchers can gain insights into the immune system's role in monitoring and eliminating B cell malignancies.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
This cell line supports the development and testing of antibodies targeting CD19. We can use the CD19 Stable Cell Line - K562 to evaluate the efficacy and specificity of antibodies, which is crucial in the development of therapeutic strategies for B-cell mediated conditions.
As K562 is a chronic myeloid leukemia cell line, the integration of CD19 into this line allows for the study of leukemia cells presenting B-cell markers. The CD19 Stable Cell Line - K562 enables us to explore novel therapeutic avenues in leukemia treatment, particularly those that target cell surface markers.
The CD19 Stable Cell Line - K562 serves as a valuable model for developing and testing CAR-T cell therapies, which are designed to target CD19 on cancerous B-cells. This application is critical for advancing CAR-T cell therapy, offering potential treatments for B-cell malignancies.
The CD19 Stable Cell Line - K562 is characterized by high cell viability and genetic stability, ensuring that experimental results are consistent and reliable. This stability is essential for long-term studies and for experiments requiring consistent expression of CD19 over extended periods.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
